

# Dana E Rathkopf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4551715/publications.pdf>

Version: 2024-02-01

80  
papers

18,078  
citations

76196

40  
h-index

66788

78  
g-index

82  
all docs

82  
docs citations

82  
times ranked

18765  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. <i>Clinical Cancer Research</i> , 2022, 28, 318-326.	3.2	28
2	Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2022, 23, e5-e6.	5.1	1
3	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 144-153.	15.2	102
4	Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide. <i>Journal of Urology</i> , 2022, 207, 1010-1019.	0.2	12
5	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
6	Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. <i>Prostate</i> , 2022, , .	1.2	3
7	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	1.3	14
8	Treating the patient and not just the cancer: therapeutic burden in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 647-661.	2.0	25
9	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	3.6	26
10	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	0.9	21
11	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	0.9	2
12	Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 1541-1559.	5.1	60
13	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2926-2937.	0.8	36
14	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 447-456.	0.9	3
15	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology Open Science</i> , 2021, 34, 70-78.	0.2	3
16	Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. <i>Cancer Cell</i> , 2020, 38, 279-296.e9.	7.7	135
17	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	5.7	45
18	A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 171-178.e2.	0.9	25

#	ARTICLE	IF	CITATIONS
19	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. <i>European Urology</i> , 2020, 78, 671-679.	0.9	72
20	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. <i>JCO Precision Oncology</i> , 2020, 4, 355-366.	1.5	93
21	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. <i>Clinical Cancer Research</i> , 2019, 25, 5623-5637.	3.2	23
22	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	3.2	17
23	Treatment of Advanced Prostate Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 479-499.	5.0	417
24	A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2019, 37, 1052-1060.	1.2	11
25	&lt;p&gt;First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 10463-10476.	0.9	56
26	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	3.4	426
27	A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2018, 36, 458-467.	1.2	61
28	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 694.	3.4	46
29	Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1521-1539.	0.8	51
30	Apalutamide for the treatment of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 823-836.	1.1	29
31	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017, 71, 656-664.	0.9	67
32	Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. <i>Clinical Cancer Research</i> , 2017, 23, 3544-3551.	3.2	72
33	Clinical Outcomes from Androgen Signaling&acircledirected Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017, 72, 10-13.	0.9	32
34	Enzalutamide in Men with Chemotherapy-na&acirclev Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVA&acircle Study. <i>European Urology</i> , 2017, 71, 151-154.	0.9	306
35	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	286
36	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	1,266

#	ARTICLE	IF	CITATIONS
37	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. <i>European Urology</i> , 2016, 70, 963-970.	0.9	104
38	Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 438-444.	0.9	31
39	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
40	Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3774-3781.	3.2	21
41	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. <i>European Urology</i> , 2016, 69, 924-932.	0.9	22
42	Novel and next-generation androgen receptor–directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 348-355.	0.8	30
43	Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. <i>Cancer</i> , 2015, 121, 3853-3861.	2.0	27
44	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
45	Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. <i>European Urology</i> , 2015, 68, 570-577.	0.9	50
46	Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America. <i>Prostate</i> , 2015, 75, 836-844.	1.2	17
47	Improvements in Radiographic Progression-Free Survival Stratified by <i>ERG</i> Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. <i>Clinical Cancer Research</i> , 2015, 21, 1621-1627.	3.2	51
48	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 152-160.	5.1	1,100
49	A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1714-1724.	1.3	30
50	Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 1277-1284.	0.2	65
51	Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e305-e309.	0.9	30
52	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	0.9	35
53	Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 147-147.	0.8	3
54	Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).. <i>Journal of Clinical Oncology</i> , 2015, 33, 169-169.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302.. Journal of Clinical Oncology, 2015, 33, 184-184.	0.8	8
56	Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.. Journal of Clinical Oncology, 2015, 33, 142-142.	0.8	0
57	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. Journal of Clinical Oncology, 2014, 32, 3391-3399.	0.8	110
58	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014, 159, 176-187.	13.5	1,184
59	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. New England Journal of Medicine, 2014, 371, 424-433.	13.9	2,456
60	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). European Urology, 2014, 66, 815-825.	0.9	221
61	The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer. Current Clinical Urology, 2014, , 77-94.	0.0	0
62	A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 537-544.	1.1	75
63	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 1193-1199.	5.1	142
64	Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 3525-3530.	0.8	223
65	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine, 2013, 368, 138-148.	13.9	2,412
66	Phase I pharmacokinetic and biodistribution study with escalating doses of <sup>223</sup> Ra-dichloride in men with castration-resistant metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1384-1393.	3.3	160
67	Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer. Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Overl	1.0	106
68	Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2013, 18, 163-173.	1.9	145
69	Repetitively dosed docetaxel and <sup>153</sup> samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer, 2013, 119, 3186-3194.	2.0	23
70	A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 69, 1089-1097.	1.1	30
71	A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs, 2011, 29, 1004-1012.	1.2	38
72	Case Series of Dermatologic Events Associated With the Insulin-Like Growth Factor Receptor 1 Inhibitor Cixutumumab. Journal of Clinical Oncology, 2011, 29, e638-e640.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 880-887.	3.2	42
74	A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1113-1121.	1.1	25
75	A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 181-189.	1.1	109
76	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1 study. <i>Lancet</i> , The, 2010, 375, 1437-1446.	6.3	972
77	Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2436-2442.	0.8	92
78	Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 7405-7411.	3.2	44
79	Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Tj ETQq1 1 0.784314 rrgBT /Over 2.0 184	2.0	184
80	Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2959-2965.	0.8	31